Skip to main content

INVO Fertility, Inc.

corporate_fare Company Profile

INVO Fertility, Inc.

IVF·NASDAQ·Industrial Applications And Services·CIK 0001417926

INVO Fertility, Inc. is a healthcare services and technology company focused on the fertility marketplace, dedicated to expanding access to assisted reproductive technology ("ART") care. The company's principal commercial strategy involves acquiring, establishing, and operating fertility clinics and related businesses and technologies. Its acquisition strategy targets US-based, profitable fertility clinics. INVO Fertility's clinics provide a variety of fertility services, including in vitro fertilization ("IVF") and the intravaginal culture ("IVC") procedure, which is enabled by its INVOcell® medical device ("INVOcell"). As of the date of this filing, INVO Fertility operates four fertility clinics in the United States. The company also sells and distributes its INVOcell technology solution to third-party owned and operated fertility clinics. Additionally, INVO Fertility plans to seek out and license or acquire additional, innovative fertility-focused technologies for use within its clinics. On February 18, 2026, the company completed the acquisition of Family Beginnings, an Indiana-based fertility clinic that offers both IVF and IVC. All information is as of December 31, 2025, unless otherwise indicated.

INVO Fertility, Inc. (NASDAQ:IVF) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors IVF SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Registers Resale of 9.4M Shares from Inducement Warrants, Creating Significant Market Overhang
  • INVO Fertility Secures $7.5M Capital Through Warrant Exercise and Issues New Warrants
  • Shareholders Approve Massive Increase in Authorized Shares, Enabling Significant Future Dilution
  • INVO Fertility realigns executive leadership, appointing new CFO and strategic Chief Business Officer to drive growth

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$6.84M
Net Income
-$23.32M
Diluted EPS
-$214.64
Op. Cash Flow
-$7.01M
Free Cash Flow
-$7.06M
Gross Profit
$6.81M
Operating Income
-$7.24M
Cash & Equivalents
$2.08M
Total Debt
$2.02M
Debt / Equity
0.28×
Net Margin
-340.9%
Shares Outstanding
477.37K sh
Source: 10-K · filed 2026-06-12 · accession 0001493152-26-028454
$0.9499
52-week range · as of 2026-07-24 $0.9499 – $102.4
Market cap
$1.7M
Volume
150K (0.0× avg)
3-mo avg 4.4M
Live data · 2026-07-27 19:44 UTC · Market open

show_chartPrice Chart

Loading chart...

feed IVF - Filings & News (Page 2)

IVF
Feb 02, 2026, 4:47 PM EST
Filing Type: S-1
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.9499 info
Change: Reverse Stock Split info
Market Cap: $1.697M info
IVF
Jan 30, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.37
Real-time Price: $0.9499 info
Change: Reverse Stock Split info
Market Cap: $1.697M info
IVF
Jan 26, 2026, 5:03 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.22
Real-time Price: $0.9499 info
Change: Reverse Stock Split info
Market Cap: $1.697M info
IVF
Jan 06, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9546
Real-time Price: $0.9499 info
Change: Reverse Stock Split info
Market Cap: $1.697M info